Qiagen and Agilent Form Marketing Alliance

An agreement to co-market their lab-on-a-chip instruments and consumables for handling nucleic acids and proteins has been announced by Qiagen (Venlo, The Netherlands) and Agilent Technologies, Inc. (Palo Alto, USA).

Under the agreement, both companies will market the Agilent 2100 bioanalyzer and LabChip kits with Qiagen's consumables and instruments. Qiagen has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification, and amplification as well as automated instrumentation and synthetic nucleic acid products. Agilent's bioanalyzer 2100 and LabChip kits are established as a leading microfluidics-based system for analyzing RNA, DNA, proteins, and cell fluorescence. The kits measure both sample quality and quantity in a single step.

As part of the nonexclusive agreement, the two companies will also develop a series of scientific application notes that describe challenging or novel applications that can be more easily accomplished using their combined products. Initial application areas are expected to include biologic sample preparation and multiplex polymerase chain reaction (PCR).

"The Agilent 2100 bioanalyzer has substantial advantages over alternative sample analysis techniques, such as gel electrophoresis and fluorescence microscopy, and combined with the high quality of Qiagen's preparative solutions, it provides a very convenient and easy-to-use method for obtaining the highest quality results,” said Metin Colpan, CEO of Qiagen.





Related Links:
Qiagen
Agilent